Trial reportCancer cell2025
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF
Abstract readClinical Trial, Phase IIClinical Trial, Phase I
In one paragraph
Trial report in Cancer cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Heating the Cold: Overcoming Immunotherapy Resistance in Microsatellite-Stable Colorectal Cancer: A Systematic Review.Molecules (Basel, Switzerland) · 2026Pooled it
- Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.British journal of cancer · 2026Trial
- Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.Oncoimmunology · 2026Article
- Impact of non-genetic heterogeneity of BRAF-mutant colon cancer organoids on growth kinetics, drug sensitivity and Wnt dynamics.International journal of cancer · 2026Article
- Review
- Prolonged response to pembrolizumab in BRAFV600E microsatellite stable metastatic colorectal cancer following an increase in tumor mutational burden.The oncologist · 2026Article
- Review
- Small and Large Extracellular Vesicles in Circulation of Diffuse Large B-Cell Lymphoma Patients Originate From Different Cell Types of the Tumor Microenvironment.Journal of extracellular vesicles · 2026Article
- Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib.Journal of clinical medicine · 2026Review
- BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Molecular biomedicine · 2026Review
- Decoding Immunotherapy Response in Colorectal Cancer: Translational Insights Beyond MSI.Cancers · 2026Review
- Confounding factors and biases abound when predicting molecular biomarkers from histological images.Nature biomedical engineering · 2026Article
- Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo.Cancer research communications · 2026Article
- Immune microenvironment evolution across the serrated neoplasia pathway and its relevance to immunotherapy.Frontiers in oncology · 2026Review
- Immune-related deubiquitylation spectrum of microsatellite stability colorectal cancer reveals USP7 as a potential immunotherapeutic target.Molecular cancer · 2025Article
- Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes inESMO gastrointestinal oncology · 2023Article
- Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Van K MorrisDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA. Electronic address: vkmorris@mdanderson.org.
Christine M ParseghianDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Vahid BahrambeigiDepartments of Translational Molecular Pathology, Houston, TX 77030, USA; Sheikh Ahmed Center for Pancreatic Cancer, The University of Texas - MD Anderson Cancer Center, Houston, TX 77030, USA.
Nourhan AbdelfattahDepartment of Neurology, Houston Methodist Research Institute, Houston, TX 77030, USA.
Lianchun XiaoDepartments of Biostatistics, Houston, TX 77030, USA.
Anjali AgrawalDepartment of Computer Science, The University of Texas at Austin, Austin, TX 78712, USA.
Kangyu LinDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Kanwal P S RaghavDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Robert A WolffDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Arvind DasariDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Ryan W HueyDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Bryan K KeeDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Michael J OvermanDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Jason A WillisDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Phat H LeDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Michelle EscanoDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Yunyu C BaigDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Kelsey PanDepartments of Cancer Medicine, Houston, TX 77030, USA.
David MenterDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Alda L TamDepartments of Interventional Radiology, Houston, TX 77030, USA.
Wai C FooDepartments of Pathology, Houston, TX 77030, USA.
Li ShenBioinformatics and Computational Biology, The University of Texas- MD Anderson Cancer Center, Houston, TX 77030, USA; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
Hey Min LeeDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
Thomas D GallupEMPIRI, Houston, TX 77030 USA.
Cori MargainEMPIRI, Houston, TX 77030 USA.
Dave GallupEMPIRI, Houston, TX 77030 USA.
Kimal I RajapaksheDepartments of Translational Molecular Pathology, Houston, TX 77030, USA; Sheikh Ahmed Center for Pancreatic Cancer, The University of Texas - MD Anderson Cancer Center, Houston, TX 77030, USA.
Paola A GuerreroDepartments of Translational Molecular Pathology, Houston, TX 77030, USA; Sheikh Ahmed Center for Pancreatic Cancer, The University of Texas - MD Anderson Cancer Center, Houston, TX 77030, USA.
Jing WangDepartments of Biostatistics, Houston, TX 77030, USA.
Ryan B CorcoranMassachussetts General Hospital, Boston, MA 02114, USA.
Anirban MaitraDepartments of Translational Molecular Pathology, Houston, TX 77030, USA; Sheikh Ahmed Center for Pancreatic Cancer, The University of Texas - MD Anderson Cancer Center, Houston, TX 77030, USA; Departments of Pathology, Houston, TX 77030, USA.
Kyuson YunDepartment of Neurology, Houston Methodist Research Institute, Houston, TX 77030, USA; EMPIRI, Houston, TX 77030 USA; Department of Neurology, Weill Cornell Medical College, Houston, TX 77030, USA.
Scott KopetzDepartments of Gastrointestinal Medical Oncology, Houston, TX 77030, USA.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MPaul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0MProject 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT · 2019 to 2023
$11.0MClinical Validation Center for Early Detection of Pancreatic CancerU01CA200468 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIRBAN MAITRA · 2016 to 2026
$11.0MLongitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsiesR01CA218230 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT, MAITRA, ANIRBAN · 2018 to 2022
$3.3MValidation of a novel 3D culture platform for TNBC treatment selectionR01CA271682 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI GALLUP, DAVID, YUN, KYUSON · 2022 to 2025
$3.0MMulti-omic liquid biopsy assessment in NCI trials: evaluating ctDNA, extravesicle RNA, and outcomes with immunotherapy in patient with colorectal and anal cancersR50CA285403 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI VAN K MORRIS · 2024 to 2026
$545kNCI NIH HHS K12 CA088084NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA221707NCI NIH HHS R01 CA218230NCI NIH HHS R01 CA271682NCI NIH HHS R50 CA285403NCI NIH HHS U01 CA200468
Abstract
The BRAF inhibitor encorafenib and anti-epidermal growth factor receptor (EGFR) antibody cetuximab modestly improve survival for patients with microsatellite stable (MSS) BRAF
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsProto-Oncogene Proteins B-rafAdultAgedCarbamatesCetuximabFemaleHumansMaleMicrosatellite InstabilityMiddle AgedMutationNeoplasm MetastasisNivolumabSulfonamidesBRAF protein, humanCarbamatesCetuximabencorafenibNivolumabProto-Oncogene Proteins B-rafSulfonamidesbiomarkerBRAFclinical trialcolorectal cancercomplement pathwayevRNAimmunotherapyMAPKmetastasisPD-1targeted therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.